These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 464786)

  • 1. [Mexiletine, a drug with anti-arrhythmic action. Experimental research on the cardiovascular system].
    Caputi AP; Rossi F; Lampa E; Imperatore A; Visone C; Marmo E
    Arch Sci Med (Torino); 1979; 136(1):1-15. PubMed ID: 464786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The anti-arrhythmic action of mexiletine: experimental study].
    Ciraolo O; Quartarone M; Corica F; D'Andrea Petrelli L; Barbera N; Ceruso D
    G Clin Med; 1983 Nov; 64(11):483-90. PubMed ID: 6667804
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of arrhythmias and of antiarrythmic activity, with special reference to mexiletine.
    Carmeliet E
    Acta Cardiol Suppl; 1980; (25):5-25. PubMed ID: 6246694
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological investigation of a new anti-arrhythmic agent, GYKI-23 107.
    Varró A; Rabloczky G; Jaszlits L; Kürthy M; Zubovics Z; Toldy L
    Drugs Exp Clin Res; 1987; 13(1):21-8. PubMed ID: 3595441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of sympathetic nervous system by mexiletine, an antiarrhythmic agent, and its antagonism against ouabain.
    Kitagawa H; Takeda F; Kohei H
    Arzneimittelforschung; 1985; 35(1A):356-9. PubMed ID: 4039173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative haemodynamic effects of lidocaine, mexiletine, and disopyramide.
    Beltrame J; Aylward PE; McRitchie RJ; Chalmers JP
    J Cardiovasc Pharmacol; 1984; 6(3):483-90. PubMed ID: 6202976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental analysis of the cardiovascular effects of acebutolol, a drug with beta-adrenolytic activity].
    Marmo E; Rossi F; Lampa E; Chieppa S; Apolito A; Del Vecchio F
    Arch Sci Med (Torino); 1978; 135(1):57-78. PubMed ID: 25058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sodium phosphocreatine and the cardiovascular and respiratory systems].
    Lampa E; Perna D; Giasi M; Imperatore A; Visone C; Somma A; Ottavo R; Matera G; Ruggiero E; Pierri T; Marmo E
    Arch Sci Med (Torino); 1981; 138(3):365-98. PubMed ID: 7032463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible adverse effects on the cardiovascular system of an antiarrhythmic drug mexiletine.
    Rossi F; Ruggiero E; Scafuro MA; Giasi M; Mazzeo V; Bile G; Lamparelli E; Marmo E
    Arch Toxicol Suppl; 1984; 7():510-4. PubMed ID: 6596024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Méxiletine. Action on heart rhythm disorders].
    Lellouche D; Bougherbal R
    Nouv Presse Med; 1975 Feb; 4(5):351-2. PubMed ID: 1093125
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias].
    Rolli A; Bonatti V; Finardi A; Favaro L; Botti G
    G Ital Cardiol; 1981; 11(4):468-76. PubMed ID: 6169578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemodynamic effects of a new anti-arrhythmic agent, mexiletine (Kö 1173) in ischaemic heart disease.
    Saunamäki
    Cardiovasc Res; 1975 Nov; 9(6):788-92. PubMed ID: 1203917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mexiletine/quinidine combination therapy: electrophysiologic correlates of anti-arrhythmic efficacy.
    Duff HJ; Mitchell LB; Wyse DG; Gillis AM; Sheldon RS
    Clin Invest Med; 1991 Oct; 14(5):476-83. PubMed ID: 1660369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mexiletine and tocainide: orally active congeners of lidocaine.
    Wulf BG
    Clin Pharm; 1983; 2(4):340-6. PubMed ID: 6411416
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effect of the new antiarrhythmic drug mexiletine on sinus node and intracardiac conduction in man (author's transl)].
    Seipel L; Breithardt G; Schoerner U
    Z Kardiol; 1978 Nov; 67(11):766-70. PubMed ID: 726555
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical study of the ventricular anti-arrhythmia effects of oral and injectable mexiletine].
    Fauchier JP; Charbonnier B; Latour F; Brochier M; Raynaud R
    Ann Cardiol Angeiol (Paris); 1978; 27(2):173-8. PubMed ID: 655605
    [No Abstract]   [Full Text] [Related]  

  • 17. [Carotid sinus baroreceptor reactivity and chemoreceptor reactivity of the carotid body in anesthetized dogs treated with endocarotid administration of beta-adrenolytics].
    Ottavo R; Marfella A; Ruta A; Pentimalli D; De Marco G; D'Angelo G; Scognamiglio M; Spadaro R; De Gennaro G
    Minerva Anestesiol; 1982 Apr; 48(4):203-8. PubMed ID: 6127654
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experimental studies of the specificity and aspecificity of a beta-adrenolytic agent, bunitrolol (Kö 1366)].
    Marmo E; Lampa E; Rossi F; Caputi AP; Chieppa S; Vacca C; Giordano L; Pedone P
    Arch Sci Med (Torino); 1978; 135(1):15-56. PubMed ID: 25057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electrophysiological study of the mexiletine (author's transl)].
    Ebagosti A; Lodovici F; Escojido H; Torresani J; Jouve A
    Ann Cardiol Angeiol (Paris); 1979; 28(3):181-8. PubMed ID: 507723
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular effects of 15(S) 15 methyl-PGF2 alpha.
    Filippelli W; Filippelli A; Caloprice A; Vacca C; Bile G; Spadaro R; Marmo E
    J Med; 1982; 13(5-6):387-98. PubMed ID: 6963330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.